About Us

Mission Statement

Radiopharmium provides expert consulting and innovative solutions for the development and production of radiopharmaceuticals. Our mission is to support the development of next-generation radiopharmaceutical technology.

Founder

Louis Allott PhD

Louis is an expert in radiochemistry and radiopharmaceutical development, with experience spanning over 14 years in academia. Holding a PhD in PET Radiochemistry, Louis has been at the forefront of innovation in radiopharmaceutical production, regulatory compliance, and method development, working with leading pharmaceutical companies, research institutions, and healthcare providers.

Throughout his career, Louis has contributed significantly to the development and production of cutting-edge radiopharmaceuticals, collaborating on projects that have led to the creation of advanced diagnostic and therapeutic agents evaluated in clinical studies. He has a proven track record of accelerating development pipelines, and generating valuable intellectual property.

Driven by a passion for advancing healthcare, Louis founded Radiopharmium with one mission: to provide expert consulting services to support the development of next-generation radiopharmaceutical technology. 

Experience

Career

2024 - Founded Radiopharmium

2024 - Honorary Lecturer at King's College London

2023 - 2024 Hull York Medical School

  • Assistant Professor in Radiochemistry & Molecular Imaging
  • PET Research Centre - Operational Lead
  • Head of Radiochemistry - Hull Molecular Imaging Centres

2021 - 2023 University of Hull

  • Assistant Professor in Translational Radiopharmaceutics

2017 - 2020 Imperial College London

  • Post-doctoral Research Associate & Chemistry Lead

2014 - 2017 Institute of Cancer Research, London

  • Post-doctoral Research Associate

2011 - 2014 PhD in PET Radiochemistry, University of Hull

2007 - 2011 Chemistry (MChem), University of Hull

Track Record

    Publications

    Underlined = first/corresponding author (or joint)

    Automated sulfur-[18F]fluoride exchange radiolabelling of a prostate specific membrane antigen (PSMA) targeted ligand using the GE FASTLab cassette-based platform; Z. Yang, C. Barnes, J. Domarkas, J. Koch-Paskowski, J. Wright, A. Amgheib, I. Renard, R. Fu, S. J. Archibald, E. O. Aboagye* and L. Allott*; RSC React. Chem. Eng., 2023

    Design, synthesis and evaluation of a novel PET imaging agent targeting lipofuscin in senescent cells; D. Brickute, C. Chen, M. Braga, C. Barnes, N. Wang, L. Allott* and E. O. Aboagye*. RSC Adv., 2022, 12, 26372-26381.

    A practical guide to automating fluorine-18 PET radiochemistry using commercially available cassette-based platforms; C. Barnes, M. Nair, E. O. Aboagye, S. J. Archibald and L. Allott*. React. Chem. Eng., 2022, 7, 2265-2279. 

    A kit-based aluminium-[18F]fluoride approach to radiolabelled microbubbles; J. H. Teh, M. Braga, L. Allott, C. Barnes, J. Hernandez-Gil, M. Tang, E. Aboagye and N. J. Long. Chem Commun, 2021, 57, 11677-11680

    The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules; S. J. Archibald and L. Allott* EJNMMI Radiopharm. Chem., 2021, 6, 30 

    Consideration of Metabolic Efflux in Radiolabelled Choline Kinetics” Y. Li, M. Inglese, S. Dubash, C. Barnes, D. Brickute, M. Braga, N. Wang, A. Beckley, K. Heinzmann, L. Allott, H. Lu, C. Chen, R. Fu, L. Carroll and E. O. Aboagye. Pharmaceutics, 2021, 13(8):1246 

    Effective Detection and Monitoring of Glioma using [18F]FPIA PET Imaging; V. Vassileva, M. Braga, C. Barnes, J. Przystal, A. Ashek, L. Allott, D. Brickute, J. M. Abrahams, K. Suwan, A. M. Carcaboso, A. Hajitou and E. O. Aboagye. Biomedicines, 2021, 9(7):811. 

    Novel non-congeneric derivatives of the choline kinase alpha inhibitor ICL-CCIC-0019 ;N. Wang, D. Brickute, M. Braga, C. Barnes, H. Lu, L. Allott* and Eric O. Aboagye*. Pharmaceutics, 2021, 13, 1078 

    Detecting hypoxia in vitro using 18F-pretargeted IEDDA “click” chemistry in live cells; L. Allott, C. Chen, M. Braga, S. F. J. Leung, N. Wang, C. Barnes, D. Brickute, L. Carroll and E. O. Aboagye. RSC Adv., 2021, 33, 20335-20341

    Radiolabelling an 18F biologic via facile IEDDA “click” chemistry on the GE FASTLab™ platform; L. Allott, A. Amgheib, C. Barnes, M. Braga, D. Brickute, N. Wang, R. Fu, S. Ghaem-Maghami and E. O. Aboagye. React. Chem. Eng., 2021, 6, 1070-1078 

    Synthesis and evaluation of 3’-[18F]fluorothymidine-5’-squaryl as a bioisostere of 3’-[18F]fluorothymidine-5’-monophosphate; D. Brickute, A. Beckley, L. Allott, M. Braga, C. Barnes, K. J. Thorley and E. O. Aboagye. RSC Adv., 2021, 20, 12423-12433 

    Chemistry considerations for the clinical translation of PET radiopharmaceuticals; L. Allott and E. O. Aboagye. Mol. Pharm., 2020; doi: 10.1021/acs.molpharmaceut.0c00328 

    Development of a fluorine-18 radiolabelled fluorescent chalcone: evaluated for detecting glycogen; L. Allott, D. Brickute, C. Chen, M. Braga, C. Barnes, N. Wang and E. O. Aboagye. EJNMMI Radiopharm. Chem., 2020; doi: 10.1186/s41181-020-00098-6 

    [18F]FET-βAG-TOCA: the design, evaluation and clinical translation of a fluorinated octreotide; L. Allott, S. Dubash and E. O. Aboagye. Cancers, 2020, 12, 856.

    Clinical Translation of 18F-Fluoropivalate - A PET Tracer for Imaging Short-Chain Fatty Acid Metabolism: Safety, Biodistribution, and Dosimetry in Fed and Fasted Healthy Volunteers; S. R. Dubash, N. Keat, K. Kozlowski, C. Barnes, L. Allott, D. Brickute, S. Hill, M. Huiban, T. Barwick, L. Kenny, E. O. Aboagye. EJNMMI, 2020; doi: 10.1007/s00259-020-04724-y 

    Solid-supported cyanoborohydride cartridges for automating reductive amination radiochemistry; L. Allott, C. Barnes, J. S. F. Leung, D. Brickute and E. O. Aboagye, React. Chem. Eng., 2019, 4, 1748-1751. 

    Synthesis of a benzoxazinthione derivative of Tanaproget and pharmacological evaluation for PET imaging of PR expression; L. Allott, C. Miranda, A. Hayes, C. Cawthorne and G. Smith, EJNMMI Radiopharm. Chem., 2019, 4, 1-20.  

    An Improved Automated Radiosynthesis of [18F]FET-βAG-TOCA”; L. Allott, C. Barnes, D. Brickute and E. O. Aboagye; React. Chem. Eng., 2019, 4, 569-574. 

    Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models; T. A. Burley, C. Da Pieve, C. D. Martins, D. M. Ciobota, L. Allott, W. J. G. Oyen, K. J. Harrington, G. Smith and G. Kramer-Marek; J. Nucl. Med., 2018, 60, 353-361.

    HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-based PET Imaging”; C. D. Martins, C. Da Pieve, T. A. Burley, R. Smith, D. M. Ciobota, L. Allott, K. Harrington, W. J.G. Oyen, G. Smith and G. Kramer-Marek; Clin. Cancer Res., 2018, 24, 1853-1865. 

    Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89”; L. Allott, C. Da Pieve, J. Meyers, T. Spinks, D.M. Ciobota, G. Kramer-Marek and G. Smith; Chem. Commun., 2017, 53, 8529-8532. 

    A general [18F]AlF radiochemistry procedure on two automated synthesis platforms; L. Allott, C. Da Pieve, D. R. Turton and G. Smith; React. Chem. Eng., 2017, 2, 68-74. 

    Efficient [18F]AlF radiolabelling of ZHER3:8698 affibody molecule for imaging of HER3 positive tumours; C. Da Pieve, L. Allott, C. D. Martins, A. Vardon, C. M. Daniela, G. Kramer-Marek and G. Smith; Bioconj. Chem., 2016, 27(8).

    Synthesis and preclinical evaluation of an [18F]fluoromethyl-Tanaproget derivative for imaging of prosterone receptor expression; S. Merchant, L. Allott, L. Carroll, V. Tittrea, S. Kealey, T. Witney, P. W. Miller, G. Smith and E. O. Aboagye; RSC Adv., 2016, 6(62).

    Development of PDT/PET Theranostics: Synthesis and Biological Evaluation of a 18F-radiolabeleld water soluble porphyrin; G. Entract, F. Bryden, J. Domarkas, H. Savoie, L. Allott, S. J. Archibald, C. Cawthorne, and R. W. Boyle; Molecular Pharmaceutics, 2015, 12(12).

    PET Imaging of Steroid Hormone Receptor Expression; L. Allott, G. Smith, E. O. Aboagye and L. Carroll; Molecular Imaging, 2015, 14(9):11-22.

    Carbon-11 Radiolabelling of Organosulfur Compounds: 11C Synthesis of the Progesterone Receptor Agonist Tanaproget; T. Haywood, S. Kealey, S. S. Cabezas, J. J. Hall, L. Allott, G. Smith, C. Plisson and P. W. Miller; Chem. Eur. J., 2015, 21(25).

    Want to discuss your project?

    Contact us today to discuss how we can help you achieve your goals.